Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
07/27/2020 07/28/2020 07/29/2020 07/30/2020 07/31/2020 Date
147.18(c) 146.83(c) 146.54(c) 146.84(c) 145.76(c) Last
5 675 155 4 842 184 4 489 147 5 922 481 8 257 997 Volume
-0.63% -0.24% -0.20% +0.20% -0.74% Change
More quotes
Financials (USD)
Sales 2020 80 530 M - -
Net income 2020 17 416 M - -
Net Debt 2020 3 827 M - -
P/E ratio 2020 22,3x
Yield 2020 2,76%
Sales 2021 87 370 M - -
Net income 2021 21 995 M - -
Net cash position 2021 5 255 M - -
P/E ratio 2021 17,7x
Yield 2021 2,90%
Capitalization 384 B 384 B -
EV / Sales 2020 4,81x
EV / Sales 2021 4,33x
Nbr of Employees 132 200
Free-Float 84,3%
More Financials
Company
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (51.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (31.6%): diagnostic systems,... 
Sector
Pharmaceuticals
Calendar
08/24Ex-dividend day for
More about the company
Surperformance© ratings of Johnson & Johnson
Trading Rating : Investor Rating :
More Ratings
Latest news on JOHNSON & JOHNSON
07:15aGilead Shows the Dangers of Covid-19 Drug Mania -- Heard on the Street
DJ
07/31Large U.S. COVID-19 vaccine trials will exclude pregnant women for now
RE
07/31JOHNSON & JOHNSON : - U.S. Food and Drug Administration Approves STELARA for Tre..
AQ
07/30JOHNSON & JOHNSON : Janssen Pharma Says FDA Approves Stelara for Pediatric Patie..
DJ
07/30JOHNSON & JOHNSON : vaccine produces 'robust' immune response in monkeys
AQ
07/30J&J starts human study of COVID-19 vaccine after promising monkey data
RE
07/30JOHNSON & JOHNSON : Covid-19 Vaccine Candidate Elicits Strong Immune Response in..
DJ
07/30JOHNSON & JOHNSON : The End Of Waiver Of Tort
AQ
07/30JOHNSON & JOHNSON : Single Dose of Johnson & Johnson COVID-19 Vaccine Candidate ..
PR
07/24JOHNSON & JOHNSON : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ..
AQ
07/24JOHNSON & JOHNSON : Janssen Gets CHMP Positive Opinion for Expanded Use of Imbru..
DJ
07/24JOHNSON & JOHNSON : Aleafia Health Approved by Janssen Pharmaceuticals to Admini..
AQ
07/22EXCLUSIVE : Novavax executives could get big payday even if vaccine fails
RE
07/21Pharma Companies Split on Coronavirus Vaccine Pricing Plans
DJ
07/21JOHNSON & JOHNSON : On Pace for Longest Winning Streak Since June 2019 -- Data T..
DJ
More news
News in other languages on JOHNSON & JOHNSON
07:15aGilead Shows the Dangers of Covid-19 Drug Mania -- Heard on the Street
07/31Large U.S. COVID-19 vaccine trials will exclude pregnant women for now
07/31JOHNSON & JOHNSON : - U.S. Food and Drug Administration Approves STELARA for Tre..
07/30JOHNSON & JOHNSON : Janssen Pharma Says FDA Approves Stelara for Pediatric Patie..
07/30JOHNSON & JOHNSON : vaccine produces 'robust' immune response in monkeys
More news
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 163,53 $
Last Close Price 145,76 $
Spread / Highest target 24,9%
Spread / Average Target 12,2%
Spread / Lowest Target -3,27%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-0.08%383 760
ROCHE HOLDING AG0.67%296 096
PFIZER, INC.-1.79%213 750
MERCK & CO., INC.-11.78%202 534
NOVARTIS AG-17.88%182 470
ABBVIE INC.7.19%167 264